These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17123282

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Hepatopulmonary syndrome and portopulmonary hypertension in the model for end-stage liver disease (MELD) era.
    Mandell MS.
    Liver Transpl; 2004 Oct; 10(10 Suppl 2):S54-8. PubMed ID: 15382220
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era.
    Iyer VN, Swanson KL, Cartin-Ceba R, Dierkhising RA, Rosen CB, Heimbach JK, Wiesner RH, Krowka MJ.
    Hepatology; 2013 Jun; 57(6):2427-35. PubMed ID: 22996424
    [Abstract] [Full Text] [Related]

  • 26. [Clinical value of the model for end-stage liver disease score in predicting the prognosis of liver transplantation in patients with end-stage liver disease].
    Sun J, Guo ZH, Lai TS, Tang YQ, Su L, Huo F, Wang SP, Pu MS, Wen Q.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1731-2, 1742. PubMed ID: 18819907
    [Abstract] [Full Text] [Related]

  • 27. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: evidence-based patient selection.
    Freeman RB.
    Liver Transpl; 2004 Oct; 10(10 Suppl 2):S2-3. PubMed ID: 15382218
    [No Abstract] [Full Text] [Related]

  • 28. Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States.
    Yoo HY, Thuluvath PJ.
    Liver Int; 2005 Jun; 25(3):536-41. PubMed ID: 15910490
    [Abstract] [Full Text] [Related]

  • 29. Liver transplantation in the era of model for end-stage liver disease.
    Wang VS, Saab S.
    Liver Int; 2004 Feb; 24(1):1-8. PubMed ID: 15101994
    [Abstract] [Full Text] [Related]

  • 30. MELD-based allocation scheme for liver transplantation in Israel.
    Onaca N, Mor E.
    Isr Med Assoc J; 2006 Sep; 8(9):651-2. PubMed ID: 17058421
    [No Abstract] [Full Text] [Related]

  • 31. Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans.
    Ahmad J, Downey KK, Akoad M, Cacciarelli TV.
    Liver Transpl; 2007 Nov; 13(11):1564-9. PubMed ID: 17969210
    [Abstract] [Full Text] [Related]

  • 32. Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems.
    Gitto S, Lorenzini S, Biselli M, Conti F, Andreone P, Bernardi M.
    Dig Liver Dis; 2009 Oct; 41(10):700-6. PubMed ID: 19502118
    [Abstract] [Full Text] [Related]

  • 33. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH, Forman L, Steinberg T, Bak T, Wachs M, Kugelmas M, Everson GT, Kam I, Trotter JF.
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras.
    Kanwal F, Dulai GS, Spiegel BM, Yee HF, Gralnek IM.
    Aliment Pharmacol Ther; 2005 Jan 15; 21(2):169-77. PubMed ID: 15679767
    [Abstract] [Full Text] [Related]

  • 36. [A man with slowly progressive dyspnea on exertion].
    Laurens ST, Simons SO, Arens AI.
    Ned Tijdschr Geneeskd; 2016 Jan 15; 160():D426. PubMed ID: 27484427
    [Abstract] [Full Text] [Related]

  • 37. Liver transplantation cost in the model for end-stage liver disease era: looking beyond the transplant admission.
    Buchanan P, Dzebisashvili N, Lentine KL, Axelrod DA, Schnitzler MA, Salvalaggio PR.
    Liver Transpl; 2009 Oct 15; 15(10):1270-7. PubMed ID: 19790155
    [Abstract] [Full Text] [Related]

  • 38. Live donor liver transplantation for a child presented with severe hepatopulmonary syndrome and nodular liver lesions due to Abernethy malformation.
    Yilmaz C, Onen Z, Farajov R, Duygu OS, Doganay L, Yuksel A, Alper M, Zeytunlu M, Arikan C, Kilic M.
    Pediatr Transplant; 2017 Mar 15; 21(2):. PubMed ID: 28078819
    [Abstract] [Full Text] [Related]

  • 39. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM, ESLD-HIV Working Group Investigators.
    Liver Transpl; 2009 Sep 15; 15(9):1133-41. PubMed ID: 19718643
    [Abstract] [Full Text] [Related]

  • 40. Is the model of end-stage liver disease (MELD) valid in Israel? A critical analysis of liver transplant waiting list mortality.
    Ben-Haim M, Carmiel M, Katz P, Shabtai E, Oren R, Nakache R.
    Isr Med Assoc J; 2006 Sep 15; 8(9):605-9. PubMed ID: 17058408
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.